Everything below concerns HPLC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-08. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
=== Branching === Most common fatty acids are straight-chain compounds, with no additional carbon atoms bonded as side groups to the main hydrocarbon chain. Branched-chain fatty acids contain one or more methyl groups bonded to the hydrocarbon chain.
While majorities might signal their support for certain ideals such as "environmental consciousness" to pollsters, actual purchases do not reflect their stated views, as can be seen from their high demand for cheap but not durable clothing ("fast fashion"), or preference for rapid delivery. Overall, although more than half say they sought environmentally friendly products, only 38% are willing to pay extra for them. While majorities of older cohorts prefer American products, Generation Z is mixed on whether or not to buy goods made in China.Nostalgia is a major theme of the behavior of consumers from Generation Z. For example, 2000s vintage electronics and fashion are back in vogue by the early 2020s. Youths who came of age during the 2010s and 2020s feel nostalgic about "simpler" eras of history they have never experienced due to the uncertainties and stress of modern life, with student loan debts and the threat of terrorism being the top concerns. Despite having the reputation for "killing" many things valued by older generations, Millennials and Generation Z are nostalgically preserving Polaroid cameras, vinyl records, needlepoint, and home gardening, to name just some. In fact, while "dumb phones" (or feature phones rather than smartphones) are on the decline around the world, in the U.S., their sales are growing among Generation Z. According to a 2019 YouGov poll, 31% of the U.S. population is willing to pay for music on vinyl, including 26% of Generation Z.
This case demonstrated the rare association between Natural Killer cell lymphoma and PNP, suggesting that Natural Killer cells could be involved in the pathogenesis of PNP. The article warned clinicians to be alert to the possibility that paraneoplastic pemphigus in lymphomas not of B-cell lineage. This added to the already complex, not fully understood pathogenesis of PNP. A study in 2013 outlined the effectiveness of plasma exchange in PNP patients with benign tumors. The University of Toronto has been working to develop a form of treatment that improves the patient's overall quality of life while remaining economically achievable. They believe they have achieved this through fixed-dose rituximab. It has proven to be effective among auto-immune diseases, but the correct administration process for treating PNP is yet to be defined. The results of the study demonstrated varying levels of remission.
The enzyme is believed to act on the so-called "quinonoid" form of the starting dihydrobiopterin. This is in contrast to the enzyme dihydrofolate reductase, which normally acts on dihydrofolic acid but can also reduce the isomer, L-erythro-7,8-dihydrobiopterin.
Sources: en.wikipedia.org
== Literature == Carl-Gerd Dieris: Zur Frage der Luminiszenz von thermooxidativ geschädigten Polycarpolaktam. Eine neue Synthese des Bakterienfarbstoffes Indigoidin und seiner Tetra-N-alkylderivate. 1980. Hans Günter Schlegel: Allgemeine Mikrobiologie. Thieme Verlagsgruppe, Stuttgart 1992, ISBN 978-3-13-444607-4. Reverchon, Sylvie; Rouanet, Carine; Expert, Dominique; Nasser, William (2002-01-02). "Characterization of Indigoidine Biosynthetic Genes in Erwinia chrysanthemi and Role of This Blue Pigment in Pathogenicity". Journal of Bacteriology. 184 (3): 654–665. doi:10.1128/JB.184.3.654-665.2002. PMC 139515. PMID 11790734. Christin Schönfeld: Charakterisierung und biochemische Analyse der Indigoidin Synthease BpsA aus S. lavendulae ATCC 11924. Masterarbeit, Philipps-Universität Marburg 2012. M. Müller, S. Ausländer, D. Ausländer, C. Kemmer, M. Fussenegger: A novel reporter system for bacterial and mammalian cells based on the non-ribosomal peptide indigoidine. Metabolic Engineering 14/2012, S. 325–335 (doi:10.1016/j.ymben.2012.04.002). H. Kobayashi, Y. Nogi, K. Hirokoshi: New violet 3,3'-bipyridyl pigment purified from deep-sea microorganism Shewanella violacea DSS12. In: Extremophiles Nr. 11(2)/2012, S. 245–250. PMID 17102923.
Zalsupindole, also known by its code names DLX-001 and AAZ-A-154 and as (R)-5-methoxy-N,N-dimethyl-α-methylisotryptamine ((R)-5-MeO-α-Me-isoDMT), is non-hallucinogenic serotonin receptor agonist and psychoplastogen of the isotryptamine family related to psychedelic tryptamines such as dimethyltryptamine (DMT). It is under development for the treatment of major depressive disorder and other central nervous system disorders. The drug is taken orally. It acts as a partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors. The drug activates the serotonin 5-HT2A receptor with sufficiently high efficacy to promote neuroplasticity but not with adequate efficacy to cause psychedelic effects. It does not produce psychedelic-like effects in animals or humans but does produce antidepressant-like effects in animals. Zalsupindole was first described in the scientific literature by 2021. It was developed by David E. Olson and colleagues at the University of California, Davis and Delix Therapeutics. As of April 2026, it has successfully completed Phase 1 clinical trials, demonstrating positive safety and biomarker data. The FDA has cleared the Investigational New Drug (IND) application for a Phase 2 trial, which includes a study design for at-home administration.
SA biosynthesis is increased via isochorismate synthase (ICS) and phenylalanine ammonia-lyase (PAL) pathway in plastids. It was observed that during plant-microbe interactions, as part of the defense mechanisms, SA is initially accumulated at the local infected tissue and then spread all over the plant to induce systemic acquired resistance at non-infected distal parts of the plant. Therefore with increased internal concentration of SA, plants were able to build resistant barriers for pathogens and other adverse environmental conditions.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.